Fang B, Song Y, Zhao R C, Han Q, Lin Q
Department of Hematology, Henan Institute of Hematology, 127 Dongming Road, Zhengzhou, Henan, China.
Transplant Proc. 2007 Jun;39(5):1710-3. doi: 10.1016/j.transproceed.2007.02.091.
A 43-year-old woman with chronic hepatic graft-versus-host disease (GVHD) who failed previous immunosuppressive therapy with cyclosporine and prednisone was treated with tacrolimus starting on day 165 after allogeneic hematopoietic stem cell transplantation. Fifteen days later, tacrolimus was discontinued because of progressive deterioration of renal function. However, after changing treatment to human adipose tissue-derived mesenchymal stem cells (AMSC), we observed rapid and complete resolution of hepatic GVHD and renal toxicity. We concluded that it is worthwhile to administer AMSC as a treatment for common hepatic GVHD, particularly for atypical cases presenting as acute hepatitis.
一名43岁患有慢性肝移植物抗宿主病（GVHD）的女性，此前接受环孢素和泼尼松免疫抑制治疗失败，在异基因造血干细胞移植后第165天开始使用他克莫司治疗。15天后，由于肾功能进行性恶化，他克莫司停药。然而，在改用人类脂肪组织来源的间充质干细胞（AMSC）治疗后，我们观察到肝GVHD和肾毒性迅速且完全缓解。我们得出结论，给予AMSC治疗常见的肝GVHD是值得的，特别是对于表现为急性肝炎的非典型病例。
